Pancreatic endocrine tumors - c-erb B2 (Her-2/neu), bcl-2, and p-53 immunohistochemical testing and their value in assessing prognosis

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 1, 2008, Pages 44-47

  Proca, Daniela M ^a,b   Frankel, Wendy L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

bcl 2; c erb B2; Immunohistochemistry; p53; Pancreatic endocrine tumors; Prognosis

Indexed keywords

EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMATOXYLIN; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BENIGN TUMOR; CANCER INVASION; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; LYMPH VESSEL; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; STAINING; WORLD HEALTH ORGANIZATION;

HUMANS; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37549044605     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31802e2f08     Document Type: Article

References (24)

1. Kloppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract. 1988;183:155-168.
2. DeLellis RA. The neuroendocrine system and its tumors. An overview. Am J Clin Pathol. 2001;115(suppl 1):S5-S16.
3. Oberg K. Neuroendocrine gastrointestinal tumors. Ann Oncol. 1996;7:453-463.
4. Wick MR, Graeme-Cook FM. Pancreatic neuroendocrine neoplasms. A current summary of diagnostic, prognostic and differential diagnostic information. Am J Clin Pathol. 2001;115(suppl 1):S28-S45.
5. Heymann MF, Joubert M, Nemeth J, et al. Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumors: an analysis of 82 sporadic cases. Histopathology. 2000;36:421-432.
6. Heitz PU, Komminoth P, Perren A, et al. Pancreatic endocrine tumors: introduction. In: Delellis RA, Lloyd RV, Heitz PU, et al, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004:177-182.
7. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in non-functioning pancreatic endocrine tumors. Virchows Arch. 1996;429:323-333.
8. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumors of the duodenopancreatic area. Gut. 1998;43:422-427.
9. Wang DG, Johnston CF, Buchanan KD. Oncogene expression in gastropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer. 1997;80:668-675.
10. Evers BM, Rady PL, Tyring SK, et al. Amplification of the Her-2/neu protooncogene in human endocrine tumors. Surgery. 1992;112:211-218.
11. Micke P, Hengstler JG, Ros R, et al. C-erb B2 expression in small cell lung carcinoma is associated with poor prognosis. Int J Cancer. 2001;92:474-479.
12. Goebel SU, Iwamoto M, Raffeld M, et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth and aggressiveness. Cancer Res. 2002;62:3702-3720.
13. Vlasoff DM, Baschinsky DY, De Y, et al. C-erb B2 (Her-2/neu) is neither overexpressed nor amplified in hepatic neoplasms. Appl Immunohistochem Mol Morphol. 2002;10:237-241.
14. Atasoy P, Bozdogan O, Ozturk S, et al. Bcl-2 expression and its correlation with neuroendocrine differentiation in colon cancer. Tumori. 2004;90:233-238.
15. Piro LD. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology. 2004;18(13 suppl 10):5-10.
16. Bartz C, Ziske C, Wiedenmann B, et al. p53 tumor suppressor gene expression in pancreatic neuroendocrine tumor cells. Gut. 1996;38:403-409.
17. Capella C, Polack JM, Buffa R, et al. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural and biochemical study of 32 cases. Cancer. 1983;52:1860-1874.
18. Solcia E, Capella C, Kloppel G. Tumors of the Pancreas. 3rd series. Washington, DC: Armed Forces Institute of Pathology; 1997.
19. Maurer CA, Glaser C, Reubi JC, et al. Carcinoid of the pancreas. Digestion. 1997;58:410-414.
20. Delle Fave G, Capurso G, Milione M, et al. Endocrine tumors of the stomach. Best Pract Res Clin Gastroenterol. 2005;19:659-673.
21. Wilkinson N, Hasleton PS, Wilkes S, et al. Lack of c-erb-2 protein in pulmonary carcinoid tumors. J Clin Pathol. 1991;44:343.
22. Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with metaanalysis. J Cancer. 2003;89:55-64.
23. Imam H, Gobl A, Eriksson B, et al. Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action. Anticancer Res. 1997;17:4659-4665.
24. Jiang SX, Kameya T, shinada J, et al. The significance of frequent and independent p53 and bcl-2 expression in large cell neuroendocrine carcinomas of the lung. Mod Pathol. 1999;12:362-369.